Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD191 in healthy volunteers and autoimmune disease
NCT06488209Phase 1Completed
- Sponsor
- Almirall
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of ALM27134 (12 arms), sponsored by Almirall. Primary endpoints: Adverse Events at 94 days, Dose-limiting Adverse Reactions at 94 days and 4 more. Started Jul 2022; status: completed.
02
Drugs
ALM27134
Beyond the preview
Go deeper on NCT06488209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488209.